Hepatic encephalopathy pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by one other user not shown)
Line 9: Line 9:


=== Pathogenesis ===
=== Pathogenesis ===
Following important aspects about [[pathophysiology]] of hepatic encephalopathy need to be understood:<ref name="pmid21857820">{{cite journal| author=Frederick RT| title=Current concepts in the pathophysiology and management of hepatic encephalopathy. | journal=Gastroenterol Hepatol (N Y) | year= 2011 | volume= 7 | issue= 4 | pages= 222-33 | pmid=21857820 | doi= | pmc=3127024 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21857820  }} </ref><ref name="pmid11232201">{{cite journal| author=Jones EA| title=Pathogenesis of hepatic encephalopathy. | journal=Clin Liver Dis | year= 2000 | volume= 4 | issue= 2 | pages= 467-85 | pmid=11232201 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11232201  }} </ref><ref name="pmid27335836">{{cite journal| author=Cordoba J| title=Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. | journal=ISRN Hepatol | year= 2014 | volume= 2014 | issue=  | pages= 236268 | pmid=27335836 | doi=10.1155/2014/236268 | pmc=4890879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27335836  }} </ref><ref name="pmid26041962">{{cite journal| author=Aldridge DR, Tranah EJ, Shawcross DL| title=Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. | journal=J Clin Exp Hepatol | year= 2015 | volume= 5 | issue= Suppl 1 | pages= S7-S20 | pmid=26041962 | doi=10.1016/j.jceh.2014.06.004 | pmc=4442852 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26041962  }} </ref>
Following important aspects about [[pathophysiology]] of hepatic encephalopathy:<ref name="pmid21857820">{{cite journal| author=Frederick RT| title=Current concepts in the pathophysiology and management of hepatic encephalopathy. | journal=Gastroenterol Hepatol (N Y) | year= 2011 | volume= 7 | issue= 4 | pages= 222-33 | pmid=21857820 | doi= | pmc=3127024 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21857820  }} </ref><ref name="pmid11232201">{{cite journal| author=Jones EA| title=Pathogenesis of hepatic encephalopathy. | journal=Clin Liver Dis | year= 2000 | volume= 4 | issue= 2 | pages= 467-85 | pmid=11232201 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11232201  }} </ref><ref name="pmid27335836">{{cite journal| author=Cordoba J| title=Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. | journal=ISRN Hepatol | year= 2014 | volume= 2014 | issue=  | pages= 236268 | pmid=27335836 | doi=10.1155/2014/236268 | pmc=4890879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27335836  }} </ref><ref name="pmid26041962">{{cite journal| author=Aldridge DR, Tranah EJ, Shawcross DL| title=Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. | journal=J Clin Exp Hepatol | year= 2015 | volume= 5 | issue= Suppl 1 | pages= S7-S20 | pmid=26041962 | doi=10.1016/j.jceh.2014.06.004 | pmc=4442852 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26041962  }} </ref>
 
* Due to the presence of scarring within the [[liver]], [[cirrhosis]] leads to obstruction of the passage of blood through the [[liver]] causing [[portal hypertension]].  
Due to the presence of scarring within the [[liver]], [[cirrhosis]] leads to obstruction of the passage of blood through the [[liver]] causing [[portal hypertension]]. This means it is difficult for blood from the [[intestine]]s to go through the liver to get back to the [[heart]]. Portal-systemic [[anastomosis|anastamoses]] ("[[shunts]]") develop, and portal blood (from the intestinal veins) will bypass the [[liver]] and return to the [[heart]] via another route without undergoing first-pass [[detoxification]] by the [[liver]].
* Portal hypertension makes it difficult for blood from the [[intestine]]s to go through the liver to the [[heart]].
 
* As a result portal-systemic [[anastomosis|anastamoses]] ("[[shunts]]") develop, and portal blood (from the intestinal veins) will bypass the [[liver]] and return to the [[heart]] via another route without undergoing first-pass [[detoxification]] by the [[liver]].
Furthermore, in [[cirrhosis]] and other forms of liver disease, the damaged liver will not be functioning as well as it should be, so even blood that does travel through the liver may not be as detoxified as it otherwise would be. In fact, if the degree of liver damage and malfunction is severe, then, even in the absence of [[portal hypertension]] and the consequent [[bypass]]<nowiki/>ing of the [[liver]] by blood coming in from the [[Intestine|intestines]], hepatic encephalopathy will still occur. Such may well be the case, for example, following severe injury due to [[acetaminophen]] poisoning or acute viral infection (e.g. [[hepatitis A]]).
* Furthermore, in [[cirrhosis]] and other forms of liver disease, the liver will not be fully functional, so even blood that does travel through the liver may not be as detoxified as it otherwise would be.  
 
* The toxic substances accumulate, of which [[ammonia]] (NH<sub>3</sub>) and [[mercaptan]]s are the most common toxic substrates responsible for encephalopathy.
The toxic substances which accumulate in the setting of liver failure and affect the brain are still not well understood. They have been thought to include [[ammonia]] (NH<sub>3</sub>) and [[mercaptan]]s. [[Ammonia|Ammoni]]<nowiki/>a is normally converted to [[urea]] by the [[liver]] and, as with [[mercaptan]]s, is produced by the [[bacterium|bacteria]]l breakdown of protein in the [[intestine]].
* [[Ammonia|Ammoni]]<nowiki/>a is normally converted to [[urea]] by the [[liver]] and, as with [[mercaptan]]s, is produced by the [[bacterium|bacteria]]l breakdown of protein in the [[intestine]].
 
* [[Ammonia]] and mercaptans can cross the [[blood-brain barrier]], which causes [[astrocyte]]s (support cells) to swell and subsequent inflammation.  
[[Ammonia]] can cross the [[blood-brain barrier]], where it causes the support cells of the [[brain]] ([[astrocyte]]s) to swell. The swelling of the brain tissue increases [[intracranial pressure]], and can lead to [[coma]] or death via [[Brain herniation|herniation]] of the [[Brain stem|brainstem]].
* The swelling of the brain tissue increases [[intracranial pressure]], and can lead to [[coma]] or death via [[Brain herniation|herniation]] of the [[Brain stem|brainstem]].


== Genetics ==
== Genetics ==
Line 29: Line 29:
**[[Hepatitis B]]
**[[Hepatitis B]]
**[[Hemochromatosis]]
**[[Hemochromatosis]]
**[[Wilson's disease|Wilson’s]] disease
**[[Wilson's disease|Wilson’s disease]]
**Age above 50 years
**Age above 50 years
**Male gender
**Male gender
Line 39: Line 39:
Microscopic studies of specimens from patients with hepatic encephalopathy suggests:<ref name="pmid27335836">{{cite journal| author=Cordoba J| title=Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. | journal=ISRN Hepatol | year= 2014 | volume= 2014 | issue=  | pages= 236268 | pmid=27335836 | doi=10.1155/2014/236268 | pmc=4890879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27335836  }} </ref>
Microscopic studies of specimens from patients with hepatic encephalopathy suggests:<ref name="pmid27335836">{{cite journal| author=Cordoba J| title=Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. | journal=ISRN Hepatol | year= 2014 | volume= 2014 | issue=  | pages= 236268 | pmid=27335836 | doi=10.1155/2014/236268 | pmc=4890879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27335836  }} </ref>
* [[Astrocyte|Astrocytic]] changes
* [[Astrocyte|Astrocytic]] changes
* Cellular swelling.
* Cellular swelling


==References==
==References==

Latest revision as of 22:12, 22 January 2018

Hepatic encephalopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatic Encephalopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatic encephalopathy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatic encephalopathy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatic encephalopathy pathophysiology

CDC on Hepatic encephalopathy pathophysiology

Hepatic encephalopathy pathophysiology in the news

Blogs on Hepatic encephalopathy pathophysiology

Directions to Hospitals Treating Hepatic encephalopathy

Risk calculators and risk factors for Hepatic encephalopathy pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Due to the presence of scarring within the liver, cirrhosis leads to obstruction of the passage of blood through the liver causing portal hypertension. This means it is difficult for blood from the intestines to go through the liver to get back to the heart. Portal-systemic anastamoses ("shunts") develop, and portal blood (from the intestinal veins) will bypass the liver and return to the heart via another route without undergoing first-pass detoxification by the liver. The toxic substances which accumulate in the setting of liver failure and affect the brain have been thought to include ammonia (NH3) and mercaptans. Ammonia is normally converted to urea by the liver and, as with mercaptans, is produced by the bacterial breakdown of protein in the intestines. Ammonia can cross the blood-brain barrier, where it causes the support cells of the brain (astrocytes) to swell. The swelling of the brain tissue increases intracranial pressure, and can lead to coma or death via herniation of the brainstem. Disorders and conditions such as alcoholic liver disease, hepatitis C, hepatitis B, hemochromatosis, Wilson disease, age above 50 years and male gender may lead to hepatic encephalopathy.

Pathophysiology

Pathogenesis

Following important aspects about pathophysiology of hepatic encephalopathy:[1][2][3][4]

Genetics

There is no established relation between hepatic encephalopathy and genetic inheritance.

Associated Conditions

Any disorders with liver failure may lead to hepatic encephalopathy.

Microscopic Pathology

Microscopic studies of specimens from patients with hepatic encephalopathy suggests:[3]

References

  1. Frederick RT (2011). "Current concepts in the pathophysiology and management of hepatic encephalopathy". Gastroenterol Hepatol (N Y). 7 (4): 222–33. PMC 3127024. PMID 21857820.
  2. Jones EA (2000). "Pathogenesis of hepatic encephalopathy". Clin Liver Dis. 4 (2): 467–85. PMID 11232201.
  3. 3.0 3.1 Cordoba J (2014). "Hepatic Encephalopathy: From the Pathogenesis to the New Treatments". ISRN Hepatol. 2014: 236268. doi:10.1155/2014/236268. PMC 4890879. PMID 27335836.
  4. Aldridge DR, Tranah EJ, Shawcross DL (2015). "Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation". J Clin Exp Hepatol. 5 (Suppl 1): S7–S20. doi:10.1016/j.jceh.2014.06.004. PMC 4442852. PMID 26041962.
  5. Schuppan D, Afdhal NH (2008). "Liver cirrhosis". Lancet. 371 (9615): 838–51. doi:10.1016/S0140-6736(08)60383-9. PMC 2271178. PMID 18328931.
  6. Nusrat S, Khan MS, Fazili J, Madhoun MF (2014). "Cirrhosis and its complications: evidence based treatment". World J Gastroenterol. 20 (18): 5442–60. doi:10.3748/wjg.v20.i18.5442. PMC 4017060. PMID 24833875.
  7. Zhou WC, Zhang QB, Qiao L (2014). "Pathogenesis of liver cirrhosis". World J Gastroenterol. 20 (23): 7312–24. doi:10.3748/wjg.v20.i23.7312. PMC 4064077. PMID 24966602.
  8. Nguyen DL, Morgan T (2014). "Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view". Hepatol Int. 8 (2): 447–51. doi:10.1007/s12072-013-9497-1. PMC 4267851. PMID 25525477.
  9. Ferenci P (2017). "Hepatic encephalopathy". Gastroenterol Rep (Oxf). 5 (2): 138–147. doi:10.1093/gastro/gox013. PMC 5421503. PMID 28533911.
  10. Klempnaue J, Schrem H (2001). "Review: surgical shunts and encephalopathy". Metab Brain Dis. 16 (1–2): 21–5. PMID 11726084.

Template:WH Template:WS